Structure-activity studies of cerulenin analogues as protein palmitoylation inhibitors

Journal of Medicinal Chemistry

Volumn 42, Issue 24, 1999, Pages 4932-4941

  Lawrence, David S ^a   Zilfou, Jack T ^a   Smith, Charles D ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERULETIDE; FATTY ACID SYNTHASE; PALMITIC ACID; PROTEIN P21;

ARTICLE; CELL PROLIFERATION; CYTOTOXICITY; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; ONCOGENE H RAS; ONCOGENE N RAS; ONCOGENE RAS; PALMITOYLATION; PROTEIN PROCESSING; STRUCTURE ACTIVITY RELATION;

ALKYL AND ARYL TRANSFERASES; AMIDES; ANTINEOPLASTIC AGENTS; CELL DIVISION; CERULENIN; ENZYME INHIBITORS; EPOXY COMPOUNDS; FARNESYLTRANSTRANSFERASE; FATTY ACID SYNTHETASE COMPLEX; HUMANS; MOLECULAR STRUCTURE; ONCOGENE PROTEIN P21(RAS); PALMITIC ACID; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 0033518174     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980591s     Document Type: Article

References (47)

1. Barbacid, M. Ras genes. Annu. Rev. Biochem. 1987, 56, 779-827.
2. Lowy, D. R.; Willumsen, B. M. Function and regulation of ras. Annu. Rev. Biochem. 1993, 62, 851-891.
3. Khosravi-Far, R.; Der, C. J. The ras signal transduction pathway. Cancer Metastasis Rev. 1994, 13, 67-89.
4. Sigal, I. S.; Smith, G. M.; Jurnak, F.; Marsico-Ahern, J. D.; D'Alonzo, J. S.; Scholnick, E. M.; Gibbs, J. B. Molecular approaches towards an anti-ras drug. Anti-Cancer Drug Des. 2 1987, 107-115.
5. Gibbs, J. B.; Oliff, A.; Kohl, N. E. Farnesyltransferase inhibitors: ras research yields a potential cancer therapeutic. Cell 1994, 77, 175-178.
6. Bolton, G. L.; Sebolt-Leopold, J. S.; Hodges, J. C. Ras oncogene directed approaches in cancer chemotherapy. Ann. Rep. Med. Chem. 1994, 29, 165-174.
7. Willumsen, B. M.; Christensen, A. The p21 ras C-terminus is required for transformation and membrane association. Nature 1984, 310, 583-586.
8. Hancock, J. F.; Magee, A. I.; Childs, J. E.; Marshall, C. J. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 1989, 57, 1167-1177.
9. Hancock, J. F.; Paterson, H.; Marshall, C. J. A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21 ras to the plasma membrane. Cell 1990, 6, 133-139.
10. Cadwallader, K. A.; Paterson, H.; MacDonald, S. G.; Hancock, J. F. N-terminally myristoylated ras proteins require palmitoylation or a polybasic domain for plasma membrane localization. Mol. Cell. Biol. 1994, 14, 4722-4730.
11. Pompliano, D. L.; Rands, E.; Schaber, M. D.; Mosser, S. D.; Anthony, N. J.; Gibbs, J. B. Steady-state kinetic mechanism of Ras farnesyl:protein transferase. Biochemistry 1992, 31, 3800-3807.
12. Chen, W.-J.; Andres, D. A.; Goldstein, J. L.; Russell, D. W.; Brown, M. S. cDNA cloning and expression of the peptide binding subunit of rat p21 ras farnesyltransferase, the counterpart of yeast RAM1/DPR1. Cell 1991, 66, 327-334.
13. Kohl, N. E.; Mosser, S. D.; deSolms, S. J.; Giuliani E. A.; Pompliano, D. L.; Graham, S. L.; Smith, R. L.; Scholnick, E. M.; Oliff, A.; Gibbs, J. B. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 1993, 260, 1934-1937.
14. James, G. L.; Goldstein, J. L.; Brown, M. S.; Rawson, T. E.; Somers, T. C.; McDowell, R. S.; Crowley, C. W.; Lucas, B. K.; Levinson, A. D.; Marsters, J. C., Jr. Benzodiazepine peptidomimetics: potent inhibitors of ras farnesylation in animal cells. Science 1993, 260, 1937-1942.
15. James, G. L.; Goldstein, J. L.; Brown, M. S. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J. Biol. Chem. 1995, 270, 6221-6226.
16. Rowell, C. A.; Kowalczyk, J. J.; Lewis, M. D.; Garcia, A. M. Direct demonstration of geranylgeranylation and farnesylation of Kiras in vivo. J. Biol. Chem. 1997, 272, 14093-14097.
17. Whyte, D. B.; Kirschmeier, P.; Hockenberry, T. N.; Nunez-Oliva, I.; James, L.; Catino, J. J.; Bishop, W. R.; Pai, J. K. K- and N-ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem. 1997, 272, 14459-14464.
18. Castro, A. C.; Adams, J.; Behnke, M. L.; Chen, S.; Grenier, L.; Klunder, J. M.; McCormack, T. A.; Oalmann, C. J.; Plamondon, L.; Soucy, F.; Wong, H. Abstracts of Papers. 216th National Meeting of the American Chemical Society, Boston, MA; American Chemical Society: Washington, DC, 1998; MEDI 215.
19. Clarke, S.; Vogel, J. P.; Deschenes, R. J.; Stock, J. Posttranslational modification of the Ha-ras oncogene protein: Evidence for a third class of protein carboxy methyltransferases. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 4643-4647.
20. Magee, A. I.; Gutierrez, L.; McKay, I. A.; Marchall, C. J.; Hall, A. Dynamic fatty acylation of p21 N-ras. EMBO J. 1987, 6, 3353-3357.
21. Camp, L. A.; Hoffmann, S. L. Purification and properties of a palmitoyl-protein thioesterase that cleaves palmitate from H-ras. J. Biol. Chem. 1993, 268, 22566-22574.
22. Camp, L. A.; Verkruyse, L. A.; Afendis, S. J.; Slaughter, C. A.; Hoffmann, S. L. Molecular cloning and expression of palmitoyl-protein thioesterase. J. Biol. Chem. 1994, 269, 23212-23219.
23. ras. J. Biol. Chem. 1998, 273, 15830-15837.
24. Omura, S. The antibiotic cerulenin, a novel tool for biochemistry as an inhibitor of fatty acid synthesis. Bacteriol. Rev. 1976, 40, 681-697.
25. Pizer, E. S.; Wood, F. D.; Heine, H. S.; Romantsev, F. E.; Pasternick, G. R.; Kuhajda, F. P. Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res. 1996, 56, 1189-1193.
26. Smith, C. D.; Zilfou, J. T.; Laing, N.; Lawrence, D. S.; Dexter, D. W. Inhibition of palmitoylation of ras oncoproteins by cerulenin. Proc. Am. Assoc. Cancer Res. 1980, 40, 118.
27. Smith, C. D.; Zilfou, J. T.; Laing, N.; Varner, A. S. Cerulenin inhibits protein palmitoylation and ras function. Submitted, Cancer Res.
28. Schlessinger, M. J.; Malfer, C. Cerulenin blocks fatty acid acylation of glycoproteins and inhibits vesicular stomatitis and Sinbis virus particle formation. J. Biol. Chem. 1982, 257, 9887-9890.
29. Boekman, R. K., Jr.; Thomas, E. W. A total synthesis of DL-cerulenin: a novel fatty acid antibiotic and lipid synthesis inhibitor. J. Am. Chem. Soc. 1977, 99, 2805-2806.
30. Mani, N. S.; Townsend, C. A. A concise synthesis of (+)-cerulenin from a chiral oxiranyllithium. J. Org. Chem. 1997, 62, 636-640.
31. Ohri, H.; Emoto, S. Stereoselective synthesis of (+)- and (-)-tetrahydrocerulenin from D-glucose. The absolute configuration of cerulenin. Tetrahedron Lett. 1978, 24, 2095-2098.
32. Jakubowski, A. A.; Guziec, F. S., Jr.; Sugiera, M.; Tam, C. C.; Tischler, M. Total synthesis of (±)-cerulenin, (±)-tetrahydrocerulenin, and related compounds. J. Org. Chem. 1982, 47, 1221-1228.
33. Ohta, T.; Tsuchiyama, H.; Nozoe, S. Total synthesis of (±)-cerulenin and (±)-tetrahydrocerulenin. Heterocycles 1986, 24, 1137-1143.
34. Griffith, W. P. Preparation and use of tetra-n-butylammonium per-ruthenate (TBAP reagent) and tetra-n-propylammonium per-ruthenate (TPAP reagent) as new catalytic oxidants for alcohols J. Chem. Soc., Chem. Commun. 1987, 1625-1627.
35. Griffith, W. P.; Ley, S. V. TPAP: Tetra-n-propylammonium perruthenate, a mild and convenient oxidant for alcohols. Aldrichim. Acta 1990, 23, 13-19.
36. Carr, J. B.; Durham, H. G. 3-(Benzoyl)oxiranecarboxamides. U.S. Patent 4,091,221, 1978.
37. Bodansky, M.; Bodansky, A. The Practice of Peptide Synthesis; Springer-Verlag: New York, 1994; pp 89-90.
38. Skehan, P.; Stoneng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesh, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. U.S.A. 1990, 82, 1107-1112.
39. Morisaki, N.; Funabashi, H.; Shimazawa, R.; Furukawa, J.; Kawaguchi, A.; Okuda, S.; Iwsaki, S. Effect of side-chain structure on inhibition of yeast fatty-acid synthase by cerulenin analogues. Int. J. Biochem. 1993, 211, 111-115.
40. Blumenstein, J. J.; Copeland, T. D.; Oroszlan, S.; Michejda, C. J. Synthetic non-peptide inhibitors of HIV protease. Biochem. Biophys. Res. Commun. 1989, 163, 980-987.
41. Blumenstein, J. J.; Michejda, C. J.; Oroszlan, S.; Copeland, T. D. U.S. Patent 5,190,969, 1993.
42. Still, W. C.; Kahn, M.; Mitra, A. Rapid chromatographic techniques for preparative separation with moderate resolution. J. Org. Chem. 1978, 43, 2923-2924.
43. Royer, G. P.; Townsend, C. A. Cerulenin compounds for fatty acid synthesis inhibition. U.S. Patent 5,539,132, 1996.
44. Corey, E. J.; Schmidt, G. Useful procedures for the oxidation of alcohols involving pyridinium dichromate in aprotic media. Tetrahedron Lett. 1979, 399-402.
45. Resh, M. D. Fatty acylation of proteins: new insights into membrane targeting of myristoylated and palmitoylated proteins. Biochim. Biophys. Acta 1999, 1451, 1-16.
46. 12]Ras is inhibited by a cytosols-localized Ras mutant. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 6630-6634.
47. Lerner, E. C.; Qian, Y.; Blaskovich, M. A.; Fossum, R. D.; Vogt, A.; Sun, J.; Cox, A. D.; Der, C. J.; Hamilton, A. D.; Sebti, S. M. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic ras signaling by inducing cytoplasmic accumulation of inactive ras-raf complexes. J. Biol. Chem. 1995, 260, 26802-26806.